A detailed history of Vident Advisory, LLC transactions in Argenx Se stock. As of the latest transaction made, Vident Advisory, LLC holds 674 shares of ARGX stock, worth $396,965. This represents 0.01% of its overall portfolio holdings.

Number of Shares
674
Holding current value
$396,965
% of portfolio
0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $239,950 - $304,344
674 New
674 $290 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $42,363 - $63,251
125 Added 27.41%
581 $221 Million
Q3 2023

Feb 21, 2024

SELL
$369.35 - $548.43 $46,168 - $68,553
-125 Reduced 21.51%
456 $224 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $168,423 - $250,084
456 New
456 $224 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.